Diabetic neuropathy is common in patients with diabetes mellitus, and 7.5% of diabetics experience pain from diabetic neuropathy. Complications of diabetes mellitus are more common where control of the disease is not optimal. By improving the control of the disease, both the neuropathy and the pain it can produce may be improved. The pain of diabetic neuropathy can frequently be controlled using analgesics, antidepressants, anticonvulsants, topical capsaicin, and neuromodulation, either alone or in any combination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0404.1999.tb07388.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diabetic foot ulcer photography study: a study within a trial to assess the reliability of two-dimensional (2D) photography for the assessment of ulcer healing in patients with diabetes-related foot ulcers-protocol paper.
BMJ Open
January 2025
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Background: The primary endpoint in diabetes-related foot ulcer (DFU) trials is often time to healing, defined as complete re-epithelialisation with absence of drainage, requiring clinical expert assessment as the gold standard. Central blinded photograph review for confirmation of healing is increasingly being undertaken for internal validity. The Diabetic Foot Ulcer Photography study aims to determine the agreement between blinded independent review panel members for assessing ulcer healing status in patients with DFUs.
View Article and Find Full Text PDFCorrelation between serum adenosine deaminase levels and risk of diabetic foot ulcers in patients with type 2 diabetes mellitus.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Orthopedics, Southwest Hospital, Army Medical University, Chongqing 400038, China.
Objectives: Adenosine deaminase (ADA) is a critical enzyme in the catabolism of adenosine acid during purine metabolism and plays a significant role in the diagnosis and monitoring of various diseases. This study aims to investigate the relationship between serum ADA levels and risk of diabetic foot ulcers (DFU) in patients with type 2 diabetes mellitus (T2DM), providing a clinical basis for the prevention and treatment of DFU.
Methods: A retrospective study was conducted on 2 719 T2DM patients diagnosed at the Southwest Hospital of Army Medical University from January 2019 to January 2020.
ASPIRIN-TRIGGERED LIPOXIN A4 REDUCES NEUROPATHIC PAIN AND ANXIETY-LIKE BEHAVIOURS IN MALE DIABETIC RATS: ANTINOCICEPTIVE ENHANCEMENT BY CANNABINOID RECEPTOR AGONISTS.
Eur J Pharmacol
January 2025
Laboratory of Pharmacology of Pain, Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
Neuropathy is the most common complication of diabetes, leading to painful symptoms like hyperalgesia. Current treatments for diabetic painful neuropathy often prove inadequate, necessitating the exploration of new pharmacological approaches. Therefore, this study aimed to investigate the potential antinociceptive effect of aspirin-triggered lipoxin A4 (ATL), a specialized pro-resolving lipid mediator, when administered alone or in combination with cannabinoid agonists, to alleviate diabetic neuropathic pain.
View Article and Find Full Text PDFBromelain-based enzymatic debridement: mechanism of action in the wound environment. A literature review.
Wounds
December 2024
MediWound, Ltd, Yavne, Israel.
Background: Chronic hard-to-heal wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, present significant safety concerns, patient burdens, and challenges to health care systems globally.
Objective: To review the mechanism of action and clinical function of bromelain-based enzymatic debridement (BBD) in the context of wound care, focusing on the mechanism of action of BBD and its formulation for chronic wounds in particular.
Methods: A literature review was conducted to assess both bromelain's mechanism of action as well as clinical and preclinical studies on the use of BBD, searching the PubMed and Google Scholar databases for articles published between November 1992 and July 2024.
Biomarkers.
Alzheimers Dement
December 2024
Clinical Research Center, Department of Medical Research, Yangon, Myanmar.
Background: Diabetes mellitus increases the risk of cognitive decline and neuronal degeneration. In diabetes, persistently elevated blood sugar levels cause not only the generation of reactive oxygen species (ROS), but also systemic inflammation (1). This raises an intriguing question: do patients with controlled or uncontrolled diabetes exhibit similar levels of oxidative stress and systemic inflammation as reliable predictors of peripheral neuropathy and cognitive decline?
Method: In 2019, 150 participants with diabetes mellitus who had been diagnosed for more than 5 years were voluntarily enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!